when it is combined with. Higher lymphocyte count is an independent factor which correlates with better response to checkpoint blockade in cancer patients. Based on the MoA of GX-I7, which induces increase of T cells in both the tumor microenvironment and peripheral blood, combining GX-I7 with pembrolizumab can potentially enhance the anti-tumor effect.

Methods This is an open-label, phase 1b/2 study in patients with refractory or recurrent TNBC who failed standard chemotherapy from 1st to 3rd line treatment in metastasis setting. Patients pretreated with cyclophosphamide received GX-I7 from 360 µg/kg up to 1,440 µg/kg every 12 weeks and pembrolizumab 200 mg every 3 weeks (n=21). Patients without cyclophosphamide pretreatment received GX-I7 from 720 µg/kg up to 1,440 µg/kg every 9 weeks or 12 weeks and pembrolizumab 200 mg every 3 weeks (n=24). The objectives were dose limiting toxicities (DLTs), safety, pharmacodynamic markers including lymphocyte increase and ORR.

Results GX-I7 and pembrolizumab were given to 45 patients (pts) (median age 50 years [29–75], ECOG PS 1 [42.2%]). 1 DLT (skin rash, Gr 3) was reported in the 1,440 µg/kg cohort. Treatment-related AEs occurred in 97.8% of pts with Gr 1–2, 15.6% with Gr 3 and 2.2% with Gr 4. Common TEAEs were injection site reaction (75.6%), rash (40.0%), pyrexia (40.0%) which were manageable. GX-I7 treatment induced up to 7-fold increase in absolute lymphocyte counts in all dose levels ranging from 360 µg/kg to 1,440 µg/kg with or without cyclophosphamide. A total of 33 evaluable mTNBC pts showed ORR of 0/3 in 360 µg/kg, 1/9 in 720 µg/kg, 2/9 in 960 µg/kg and, 4/12 in 1,200 µg/kg. Interestingly, 4 out of 6 pts received 1,200 µg/kg of GX-I7 with cyclophosphamide achieved SD and, thus, 1,200 µg/kg of GX-I7 regimens have been selected as candidates for RP2D. The tumor assessment for 1,440 µg/kg with or without cyclophosphamide is ongoing.

Conclusions GX-I7 in combination with pembrolizumab with or without cyclophosphamide was safe and well tolerated in most study participants. GX-I7 significantly increased T cell numbers in combination with pembrolizumab at doses from 360 µg/kg to 1,440 µg/kg. These results suggested GX-I7 in combination with pembrolizumab show promise as a potential treatment option for patients with metastatic TNBC.

Trial Registration ClinicalTrials.gov Identifier: NCT03752723

Ethics Approval The study was approved by the Samsung Medical Center, Gachon University Gil Medical Center, National Cancer Center, Korea University Anam Hospital, Korea University Guro Hospital, Severance Hospital, Ajou University Hospital, Seoul National University Bundang Hospital, Ewha Womans University Mokdong Hospital, Asan Medical center, Catholic Medical Center and Gangnam Severance Hospital Institutional Review Board, protocol number GX-I7-CA-006 (KEYNOTE-899).

REFERENCES

- Cortes J, Lipatov O, Im S-A. KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). *Ann. Oncol* 2019;**30**:suppl 5:859–960
- Sohn J, Park KH, Ahn HK. Preliminary safety and efficacy of GX-I7, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899). *J. Clin. Oncol* 2020;**38**:15_suppl.1072

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0322>

323

SYSTEMIC ADMINISTRATION OF LADIRATUZUMAB VEDOTIN ALONE OR IN COMBINATION WITH PEMBROLIZUMAB RESULTS IN SIGNIFICANT IMMUNE ACTIVATION IN THE TUMOR MICROENVIRONMENT IN METASTATIC BREAST CANCER PATIENTS

¹Lajos Pusztai*, ²Hailing Lu, ²Christopher Hale, ²Anne Grosse-Wilde, ³Jennifer Specht, ⁴Shanu Modi, ⁵Hyo Han, ⁶Javier Cortes, ⁷Mafalda Oliveira, ²Phillip Garfin, ²Zejing Wang, ²Matthew Onsum. ¹Yale School of Medicine, New Haven, CT, USA; ²Seattle Genetics, Bothell, WA, USA; ³Seattle Cancer Care Alliance, Seattle, WA, USA; ⁴Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵H. Lee Moffitt Cancer Ctr and Research Ctr, Tampa, FL, USA; ⁶IOB Institute of Oncology, Quiron Group, Madrid, Madrid, Spain; ⁷Vall d'Hebron University Hospital, Barcelona, Spain

Background Ladiratuzumab vedotin (LV) is an investigational antibody-drug conjugate (ADC) composed of a humanized anti-LIV-1 IgG1 conjugated with monomethyl auristatin E (MMAE), a microtubule-disrupting agent. LV targets LIV-1, a protein expressed by various cancers. Along with a cytotoxic effect, LV has been shown to induce immunogenic cell death (ICD) in preclinical studies. LV is currently being investigated as a monotherapy and in combination with pembrolizumab in patients with metastatic breast cancer and other solid tumors. This correlative biomarker study aims to assess the ability of LV to modulate the tumor microenvironment (TME) in breast cancer patients.

Methods In the SGNLVA-001 trial, metastatic breast cancer patients, predominantly of the triple negative subtype (TNBC), received LV monotherapy (2.0 or 2.5 mg/kg, every 3 weeks [q3w]). In the SGNLVA-002 trial, patients with metastatic TNBC received LV (2.0 or 2.5 mg/kg, q3w) plus pembrolizumab (200 mg, q3w). To investigate the potential effect of LV or LV plus pembrolizumab on the TME, paired pre-treatment and on-treatment tumor biopsies (Cycle [C] 1 Day [D] 5 or C1D15) were collected and analyzed by RNAseq and immunohistochemistry (IHC) staining.

Results Gene expression analysis of paired biopsy TNBC samples (n=59; baseline and C1D5) showed that LV monotherapy treatment significantly induces immune response-related gene expression, MHC, co-stimulatory molecules, and PD-L1. Gene set enrichment analysis (GSEA) demonstrated enrichment of macrophage and tumor inflammation signature genes, supporting the induction of ICD and enhancement of innate immune response. Paired tumor samples from subjects treated with LV plus pembrolizumab (n=16; baseline and C1D15) showed a broader range of gene expression changes on RNAseq compared to LV monotherapy. GSEA evidenced enrichment of genes associated with cytotoxic CD8 T cells, CD4 T helper cells, dendritic cells, and macrophages, further demonstrating the induction of ICD and activation of an innate immune response. Importantly, the combination had a unique adaptive immune response induction signature. IHC analysis confirmed the increased infiltration of macrophages after LV monotherapy. The combination with pembrolizumab resulted in a further increase in macrophages and a prominent influx of CD8 T cells.

Conclusions Systemic administration of LV monotherapy resulted in immune activation in the TME and macrophage infiltration. The combination of LV plus pembrolizumab resulted in a more potent immune activation in the TME and a prominent influx of CD8 T cells in addition to macrophages. Together these results provide a rationale for the continued clinical investigation of LV alone or in combination with pembrolizumab.

Trial Registration NCT01969643 and NCT03310957

Ethics Approval The study protocols for clinical trials represented in this publication were reviewed by the respective IRB/IEC at each study site and approved before trial participants were screened and enrolled.

Consent Not applicable.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0323>

324 BDB001, A TOLL-LIKE RECEPTOR 7 AND 8 (TLR7/8) AGONIST, CAN BE SAFELY ADMINISTERED INTRAVENOUSLY AND SHOWS CLINICAL RESPONSES IN ADVANCED SOLID TUMORS

¹Manish Patel*, ²Drew Rasco, ³Melissa Johnson, ⁴Anthony Tolcher, ⁵Lixin Li, ⁵Adam Zong, ⁵Alexander Chung, ⁵Robert Andtbacka. ¹Florida Cancer Specialists and Research, Sarasota, FL, USA; ²START Center for Cancer Care, San Antonio, TX, USA; ³Sarah Cannon Cancer Center, Nashville, TN, USA; ⁴NEXT Oncology, San Antonio, TX, USA; ⁵Seven and Eight Biopharmaceuticals Inc., Edison, NJ, USA

Background TLR agonists mediate antitumor activity through dendritic cell (DC) activation. Most TLR agonists in development are administered intratumorally allowing for less than 30% of advanced solid tumor to be treated. BDB001 is an intravenously administered novel TLR7/8 agonist that activates plasmacytoid and myeloid DCs and has shown to have activity in preclinical studies. Here we report on BDB001 administration in patients with advanced solid tumors.

Methods BDB001-101 is a Phase 1, open label, dose escalation/expansion trial of BDB001 administered intravenously weekly in patients with advanced solid tumors. The primary endpoint was safety and tolerability. Secondary endpoints included efficacy, pharmacokinetics and pharmacodynamic profiling of immune activation.

Results Thirty-six subjects with 16 different tumor types were enrolled across 5 dose levels. Sixty seven percent were female, median age was 66 years (range, 38–88), median number of prior therapies was 4 (range, 0–12), and 61% of tumors had progressed on prior anti-PD-(L)1 therapy. BDB001 was well tolerated and a maximum tolerated dose was not reached. Eleven (30.5%) subjects had no treatment related adverse events (AEs) and the majority of AEs were Grade 1 or 2. Three (8.3%) subjects had Grade 3 AEs, including 2 with a cytokine release syndrome, both of whom were clinically stable and had symptoms fully resolved within 2 to 5 days. There were no Grade 4 or 5 AEs. The most common AEs included chills/rigor (19.4%), fever (19.4%), fatigue (11.1%), nausea (11.1%) and pruritus (11.1%). Of 32 subjects evaluable for efficacy, best overall response rate was: 6% durable partial response, 56% stable disease, 38% progressive disease, for a disease control rate of 62%. Durable responses were seen in renal cell carcinoma and non-small cell lung cancer. Interestingly, clinical activity favored subjects with tumors that had progressed on prior anti-PD-(L)1 therapy, compared to prior DNA-damaging chemotherapy, within 6 months of BDB001 initiation. Median time on treatment was 12.1 weeks (range, 3.1 – 68.0). Transcriptional profiling showed up-regulation of interferon inducible genes, activation of dendritic cells and macrophages. BDB001 also significantly increased serum levels of interferon gamma and interferon inducible protein-10 (IP-10).

Conclusions Intravenously administered BDB001 monotherapy was well tolerated. Clinical responses were achieved, supported by BDB001-induced immune activation. Preliminary findings suggest that BDB001 is a promising therapeutic

option for patients with tumors that progress on anti-PD-(L)1 therapy. BDB001 is also being evaluated in combination with pembrolizumab (anti-PD-1, NCT03486301) and with atezolizumab (anti-PD-L1, NCT04196530).

Trial Registration NCT03486301

Ethics Approval This study was approved by the institutional review boards at the four participating institutions. All subjects signed informed consent before enrolling in the clinical trial.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0324>

325 IMMUNOTHERAPY WITH B CELL ACTIVATING ANTIBODY CPI-006 IN PATIENTS (PTS) WITH MILD TO MODERATE COVID-19 STIMULATES ANTI-SARS-COV-2 ANTIBODY RESPONSE, MEMORY B CELLS AND MEMORY T EFFECTOR CELLS

¹Gerard Criner*, ²Mehrdad Mobasher, ²Craig Hill, ²Shenshen Hu, ²Suresh Mahabhashyam, ³Joshua Brody, ³Thomas Marron, ²Stephen Willingham, ²Richard Miller. ¹Temple University Hospital, Philadelphia, USA; ²Corvus Pharmaceuticals Inc, Burlingame, CA, USA; ³Icahn School of Medicine at Mount Sinai, New York, NY, USA

Background CD73 is present on subsets of B and T cells and is involved in lymphocyte activation. CPI-006 is a humanized IgG1, Fcγ receptor deficient anti-CD73 that has agonistic properties. In vitro studies and ongoing cancer clinical trials show that CPI-006 binds to B cells leading to expression of CD69, trafficking to lymph nodes, immunoglobulin class switching, transformation to plasmablasts and generation of memory B cells.¹ Recently, a patient in the cancer trial with asymptomatic COVID-19 developed high titers of neutralizing anti-SARS-CoV-2 antibodies following administration of CPI-006. A phase 1 trial in COVID-19 was initiated to evaluate the use of CPI-006 to enhance anti-viral immune response (NCT04464395).

Methods Single intravenous dose escalation with N=5 per cohort of 0.3, 1.0, 3.0 and 5.0 mg/kg. Pt eligibility included PCR positive nasal swab for COVID-19; hospitalized with O₂ saturation of ≥92% on <5 l/min of O₂. Pts received standard care for COVID-19. Pts were monitored for safety, COVID-19 symptoms, inflammatory markers and anti-SARS-CoV-2 antibodies by ELISA. Immunophenotyping of blood by flow cytometry was performed.

Results 10 pts have been treated in the first 2 cohorts; median age 64 (range 28–76) and all had comorbidities: diabetes (4), hypertension (2), obesity (7) and/or cancer (2). Median duration of symptoms prior to CPI-006 was 8 days (range 1–21 days). No treatment-related adverse events were reported. There was no correlation between duration of symptoms and baseline anti-viral titers. Kinetics of anti-SARS-CoV-2 response to spike protein are shown for 7 pts with follow-up ≥ 7 days post CPI-006 (figure 1). One pt with lymphopenia (600/mm³) had delayed response to CPI-006; all other pts generated antibody response by Day 7 post-CPI-006 to both spike and RBD. Increasing titers of IgG and IgM antibodies were observed out to 28 days post treatment. In one pt examined, memory B cells increased from 1.81% to 4.83% of B cells 28 days after treatment with serum IgG titers to spike and to RBD of >1:50,000. 2 of 2 pts had increase in both CD4 and CD8 T effector memory cells at day 28. All pts were discharged (median 4 days) with clinical improvement.

Conclusions CPI-006 is well tolerated in COVID-19 pts. Low baseline titers of antibodies to virus were increased following CPI-006 in all treated pts. Immunomodulation with CPI-006